Skip to main content
Event

Biotech Dealmaking – Regulatory Considerations for the Next Wave of Development-Stage Transactions – Program and Lunch @ JPM 2026

Monday, January 12, 2026
Sidley Speakers
Torrey CopeMeenakshi DattaSally Wagner Partin

イベント詳細

日付Monday, January 12, 2026

11:30 a.m. - 2:30 p.m. PT

For questions, please contact sfevents@sidley.com.

Join members of Sidley's Global Life Sciences team for a lunchtime CLE-accredited program during the JPM Healthcare Conference discussing the latest regulatory trends impacting the next wave of development-stage transactions.

Led by Meena Datta, global co-leader of Sidley's Healthcare practice; Torrey Cope, partner in Sidley's Food Drug and Medical Device (FDMD) practice; and Sally Wagner Partin, partner in Sidley's M&A practice, this session provides keen insights on the considerations driving recent biotech dealmaking. 1 hour CLE credit available.

連絡先

Cope, Torrey
パートナー
Datta, Meenakshi
パートナー
Wagner Partin, Sally
パートナー

Offices

関連リソース

得意分野

Suggested News & Insights

A New World Order – Market Access, MFN, and GeopoliticsTuesday, November 10, 2026
Events
Sidley & Trinity Capital Life Sciences ReceptionThursday, October 22, 2026
Events
A Breakout Year for CVRs: 2025 and First-Half 2026 Trends in Life Sciences Public M&AOctober 6, 2026
Publications
Congressional Democrats Propose First Federal Corporate Practice of Medicine Law; Unlikely to PassOctober 6, 2026
Global Life Sciences Update
Sidley Represents Telix Pharmaceuticals in Its US$1.65 Billion Merger With ITMOctober 5, 2026
Announcements
GLOBE MFN (Most-Favored-Nation) Drug Pricing for Medicare Part B Significantly Narrowed in Final RuleOctober 5, 2026
Global Life Sciences Update